Literature DB >> 22003821

The role of ketogenic diet in the treatment of refractory status epilepticus.

Sook Hyun Nam1, Bo Lyun Lee, Cha Gon Lee, Hee Joon Yu, Eun Yeon Joo, Jeehun Lee, Munhyang Lee.   

Abstract

Ketogenic diet (KD) is known to be effective in intractable epilepsy. However, the role of KD in refractory status epilepticus (RSE) has not been well described. The aim of this study is to explore the role of KD in patients with RSE. We retrospectively reviewed the medical records of four children and one adult with RSE between October 2006 and August 2010. All presented with status epilepticus (SE) that was presumed to be associated with viral encephalitis. After we failed to control the seizures with standard measures for SE, we tried KD. The overall seizure frequency decreased to <50% of baseline in median eight (1-19) days. At one month of KD, two patients were seizure-free, one patient showed >90% seizure reduction, and the others had >75% decrease without generalized seizures. With improvement in the RSE, we were able to taper the antiepileptic drugs (AEDs) and wean patients from prolonged mechanical ventilation. The adverse events of KD in RSE included aspiration pneumonia, gastroesophageal reflux, constipation, and hypertriglyceridemia. Those results demonstrate that KD can be a valuable therapeutic option for patients with RSE. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003821     DOI: 10.1111/j.1528-1167.2011.03289.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  Ketogenic diet for adults in super-refractory status epilepticus.

Authors:  Kiran T Thakur; John C Probasco; Sara E Hocker; Kelly Roehl; Bobbie Henry; Eric H Kossoff; Peter W Kaplan; Romergryko G Geocadin; Adam L Hartman; Arun Venkatesan; Mackenzie C Cervenka
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

2.  Epilepsy Treatment Simplified through Mobile Ketogenic Diet Planning.

Authors:  Hanzhou Li; Jeffrey L Jauregui; Cagla Fenton; Claire M Chee; A G Christina Bergqvist
Journal:  J Mob Technol Med       Date:  2014-07

3.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

4.  Treatment of nonconvulsive status epilepticus.

Authors:  Trudy Pang; Frank W Drislane
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

5.  Ketogenic Diets for Adults With Highly Refractory Epilepsy.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Epilepsy Curr       Date:  2017 Nov-Dec       Impact factor: 7.500

Review 6.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 7.  Seizures in steroid-responsive encephalopathy.

Authors:  Xin Xu; Aolei Lin; Xuefeng Wang
Journal:  Neurol Sci       Date:  2020-11-21       Impact factor: 3.307

Review 8.  Ketogenic Diets for Adult Neurological Disorders.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 9.  The collective therapeutic potential of cerebral ketone metabolism in traumatic brain injury.

Authors:  Mayumi L Prins; Joyce H Matsumoto
Journal:  J Lipid Res       Date:  2014-04-10       Impact factor: 5.922

10.  Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A Single-Center Experience.

Authors:  Markus Breu; Chiara Häfele; Sarah Glatter; Petra Trimmel-Schwahofer; Johann Golej; Christoph Male; Martha Feucht; Anastasia Dressler
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.